



NDA 022382/S-009

**SUPPLEMENT APPROVAL**

Luitpold Pharmaceuticals, Inc.  
One Luitpold Drive, PO Box 9001  
Shirley, NY 11967

Attention: Felicia Bullock  
Sr. Director, Regulatory Affairs

Dear Ms. Bullock:

Please refer to your Supplemental New Drug Application (sNDA) dated April 8, 2013, received April 9, 2013, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Sprix (ketorolac tromethamine) Nasal Spray.

We acknowledge receipt of your amendments dated May 7, and September 30, 2013.

This "Prior Approval" supplemental new drug application proposes to update the DOSAGE AND ADMINISTRATION section to clarify that the product is intended for intranasal administration and not for inhalation, the DESCRIPTION section, and the Nursing Mothers subsection of USE IN SPECIFIC POPULATION section. Additionally, changes were proposed in to the Patient Counseling Information to clarify that the product is intended for intranasal administration and not for inhalation.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Swati Patwardhan, Regulatory Project Manager, at (301) 796-4085.

Sincerely,

*{See appended electronic signature page}*

Sharon Hertz, MD  
Deputy Director  
Division of Anesthesia, Analgesia,  
and Addiction Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SHARON H HERTZ  
04/21/2014